Revance to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Revance Therapeutics, Inc. (RVNC) will be participating in two investor conferences: Stifel 2023 Healthcare Conference and Piper Sandler 35th Annual Healthcare Conference. The Chief Financial Officer, Tobin Schilke, will participate in a fireside chat on November 14, 2023, at 11:30 A.M. EST, while the Chief Executive Officer, Mark Foley, will participate in a fireside chat on November 28, 2023, at 3:00 P.M. EST. Interested parties can access the live audio webcasts from the company's website. Webcast replays will be available for approximately 90 days.

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (RVNC), today announced that the company will be participating in the following investor conferences.

Stifel 2023 Healthcare Conference
Chief Financial Officer, Tobin Schilke, is scheduled to participate in a fireside chat on Tuesday, November 14, 2023, at 11:30 A.M. EST, in New York City, New York.

Piper Sandler 35^th Annual Healthcare Conference
Chief Executive Officer, Mark Foley, is scheduled to participate in a fireside chat on Tuesday, November 28, 2023, at 3:00 P.M. EST, in New York City, New York.

Interested parties can access the live audio webcasts for the conferences from the Investor Relations section of the company's website at www.revance.com. The webcast replays will be available after the conclusion of the live presentations for approximately 90 days.

About Revance

Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. Revance’s portfolio includes DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection and the RHA® Collection of dermal fillers in the U.S. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection and Shanghai Fosun Pharmaceutical to commercialize DAXXIFY® in China.

Revance is headquartered in Nashville, Tenn., with additional office locations in Newark and Irvine, Calif.

Learn more at www.Revance.com, www.RevanceAesthetics.com, www.DAXXIFY.com, www.hcp.DAXXIFYTherapy.com, or connect with us on LinkedIn.

“Revance” and the Revance logo, and DAXXIFY® are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA. BOTOX® is a registered trademark of Allergan, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231106067994/en/

Investors

Revance Therapeutics, Inc.:

Jessica Serra, 510-279-6886

jessica.serra@revance.com

or

Gilmartin Group, LLC.:

Laurence Watts, 619-916-7620

laurence@gilmartinir.com

Media

Revance Therapeutics, Inc.:

Sara Fahy, 949-887-4476

sfahy@revance.com

Source: Revance Therapeutics, Inc.

FAQ

What conferences will Revance Therapeutics be participating in?

Revance Therapeutics will be participating in the Stifel 2023 Healthcare Conference and the Piper Sandler 35th Annual Healthcare Conference.

Who will be participating in the fireside chats?

The Chief Financial Officer, Tobin Schilke, will participate in a fireside chat on November 14, 2023, and the Chief Executive Officer, Mark Foley, will participate in a fireside chat on November 28, 2023.

Where will the investor conferences take place?

The investor conferences will take place in New York City, New York.

How can interested parties access the webcasts?

Interested parties can access the live audio webcasts from the Investor Relations section of Revance Therapeutics' website at www.revance.com.

How long will the webcast replays be available?

The webcast replays will be available for approximately 90 days.